Welcome to our dedicated page for Myomo SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to confirm whether the Myomo myoelectric arm brace just cleared another FDA hurdle or see if executives are buying shares? This page gathers every disclosure you’ll need, from the first 8-K material events to the latest proxy statement executive compensation.
Start with the Myomo annual report 10-K simplified; Stock Titan’s AI flags sections on device reimbursement, robotics R&D spending, and patent portfolios so you don’t comb through hundreds of pages. For real-time performance updates, the Myomo quarterly earnings report 10-Q filing arrives here the moment it hits EDGAR, complete with plain-English revenue trend summaries.
Need to monitor confidence inside the C-suite? Our dashboard streams Myomo insider trading Form 4 transactions the second they’re posted. You’ll also see a separate feed of Myomo Form 4 insider transactions real-time with AI context that spotlights unusual buys or sells. Every filing type is covered:
- 8-K alerts for device approvals—Myomo 8-K material events explained
- Def 14A—Myomo proxy statement executive compensation
- 10-K, 10-Q, S-1, and more—Myomo SEC filings explained simply
Behind the scenes, our AI engine turns dense regulatory prose into clear takeaways: cash runway length, insurance reimbursement updates, and segment sales data. Whether you’re a healthcare analyst comparing robotics companies or a physician-investor understanding Myomo SEC documents with AI, the platform delivers the Myomo earnings report filing analysis and executive stock transactions Form 4 insights you need—without the technical grind.
Myomo, Inc. (MYO) – Form 4 insider transaction
Chief Medical Officer Harry Kovelman reported the automatic sale of 13,054 common shares on 30 June 2025 at $2.19 per share. The transaction is coded “F,” indicating the shares were withheld solely to cover income taxes arising from the vesting of restricted stock units on 28 June 2025. After the sale, Kovelman still beneficially owns 140,618 shares, held directly. No derivative securities were acquired or disposed of, and no additional transactions are disclosed.
The filing appears to be a routine tax-related share withholding rather than a discretionary market sale and does not materially change insider ownership levels.
Myomo, Inc. (MYO) – Form 4 filing: Chief Financial Officer David A. Henry reported a Code “F” transaction on 30 June 2025, in which 23,587 shares of common stock were withheld and sold at $2.19 per share solely to satisfy income-tax obligations arising from the vesting of restricted stock units (RSUs) on 28 June 2025. After the automatic sale, the executive continues to hold 427,900 shares in direct ownership. No derivative security activity was reported, and the filing discloses no additional purchases or open-market sales. Such tax-withholding dispositions are routine and generally neutral with respect to the executive’s long-term ownership position and the company’s fundamentals.
Myomo, Inc. (MYO) – Form 144 filing: The notice discloses a proposed sale of 23,587 common shares by David Henry through Morgan Stanley, targeted for 30 June 2025 on the NYSE American. The shares have an aggregate market value of $51,655.53, equating to roughly 0.07 % of the company’s 35,978,922 shares outstanding, indicating an immaterial proportion of total equity.
The securities derive from the vesting of restricted stock units (RSUs) on 28 June 2025, when 65,000 shares were acquired from Myomo. In addition, the filer sold 8,373 shares on 06 June 2025 for gross proceeds of $24,867.81. No other financial data or operational commentary is provided in the filing.
Because the planned sale represents a very small percentage of outstanding shares and does not involve new share issuance, dilution is not a concern. Nonetheless, investors often monitor insider transactions for sentiment signals; repeated insider selling can be interpreted cautiously, even when associated with equity compensation events such as RSU vesting.
Myomo, Inc. (MYO) – Form 144 filing: An insider has filed notice to sell up to 13,054 shares of common stock through Morgan Stanley Smith Barney. The shares are valued at an aggregate market price of $28,588.26, representing roughly 0.04 % of the company’s 35,978,922 shares outstanding. The planned sale date is 28 June 2025 on the NYSE American exchange.
The filing also discloses a prior sale by the same individual—5,743 shares sold on 6 June 2025 for gross proceeds of $17,057. The shares being offered were acquired via the vesting of 40,000 restricted stock units dated 28 June 2025. No material adverse, non-public information is known to the filer according to the required certification.
Because the proposed sale is modest in size and represents a small fraction of the float, it is unlikely to have a material impact on trading dynamics; however, investors often monitor insider activity for sentiment signals.
FAQ
What is the current stock price of Myomo (MYO)?
What is the market cap of Myomo (MYO)?
What are myoelectric orthotics?
How does Myomo generate revenue?
Who are the primary customers of Myomo?
What role do healthcare professionals play in Myomo's model?
How is Myomo's technology clinically validated?
What distinguishes Myomo from its competitors?
What benefits do patients experience using Myomo's devices?
What kind of research and educational initiatives does Myomo support?
